NCT01510951View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Psoriasis
Interventions
DRUG

AMG 811 or Placebo

Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.

Trial Locations (4)

1010

Research Site, Grafton, Auckland

4006

Research Site, Herston

6009

Research Site, Nedlands

8011

Research Site, Christchurch

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY